MPT Investment Case Slide Deck: How to use this tool

• This slide deck is intended to be used by product developers, current MPT funders, and others working in the MPT space to “make the case” for investing in MPTs.

• The slides can be used as a complete presentation or select slides can be used within presentations being developed for different audiences.

• Please credit source as IMPT Secretariat or www.theIMPT.org.
How long do we have to wait for better sexual & reproductive health options?
Multipurpose prevention technologies (MPTs) can radically advance the sexual & reproductive health of millions of women across the globe.
A global market exists for MPTs

- Contraceptive market – $20 billion
- Market for condoms alone – $8 billion
- HIV care, treatment & prevention – $48.9 billion
- Global STI treatment market – $35 billion growing to $84 billion by 2026
Cost of treating HIV continues to rise

To end AIDS as a public health threat by 2030, UNAIDS estimates $26.2 billion is needed in 2020 alone—an increase of $1.5 billion each year between 2016 and 2020.

STIs, which increase HIV risk, have risen dramatically.

Oral and topical PrEP products have not been as effective with women as with men.
More than 1/2 of reproductive aged women in Sub-Saharan Africa who want to avoid a pregnancy—55 million—are not using an effective contraceptive method

In the US, 16 million sexually active women who say they don’t want to get pregnant are not using contraception
For millions of women, sex brings great risk
89 million unintended pregnancies occur annually worldwide.

830 women die every day from pregnancy and childbirth-related complications in developing countries.
Women recognize pregnancy as a risk of sex, but HIV and STIs don’t loom as large, yet...
HIV is the leading killer of women aged 15–44 and the leading cause of death for women of reproductive age.

Worldwide, 1 million STIs are contracted every day.

Infertility—much of it related to curable STIs—is estimated to affect 186 million couples worldwide.
The burden of STIs has increased

STIs are among the leading causes of disability-adjusted life years (DALYs) lost for women of reproductive age.

Reported STIs represent only the “tip of the iceberg” as most are entirely asymptomatic.

WHO estimates that each year more than 340 million new curable STIs occur in reproductive-aged men and women.
MPTs—an innovative class of products that deliver varied combinations of HIV prevention and other STI prevention, and contraception—can be the *tipping point* in women’s sexual & reproductive health
The condom—a 2,000 year old method—is the only MPT. They work, but women often have to negotiate their use. There are literally not enough of them—1.3 billion more condoms are needed to protect at-risk sex acts.
A burgeoning field and robust pipeline

Since launching in 2009, the MPT field has seen an **upward trend** in public sector investment. $50 million invested in a pipeline of nearly 30 product candidates. A market primed for ‘disruption’ by private non-government investment.
More choices...

- Vaginal inserts and films
- Antibody-based products
- Microarray patches
- IUDs and implant technologies
- On-demand gels
- New condom designs
- New vaginal ring designs and different combinations of protection
- Co-formulated & co-encapsulated oral contraceptive MPTs
A related sector ‘Femtech’ is seeing unprecedented investment

- Software, diagnostics, products, & services that leverage technology to improve women’s health
- $241 million in VC funding in 2019, projected $1 billion by year-end and $50 billion by 2025
- Pregnancy, fertility, and STI diagnostics are key areas
Investing in MPTs can triple the impact of any single intervention

Facilitate uptake & adherence of HIV prevention products & reduce future need for antiretroviral therapy

Avert unintended & mistimed pregnancies while reducing new HIV infections & STIs

Keep people alive, avert economic loss, support rights of women
Innovation can’t wait
MPTs have the potential to usher in a similar revolution by bridging interests to produce wider results that benefit society, invigorate economies, offer more efficient prevention strategies, and strengthen the rights of women.
The Initiative for MPTs (IMPT)

- The IMPT strategically guides the MPT field by identifying priorities and gaps and developing recommendations to advance successful MPT R&D

- By uniting stakeholders working across the MPT field, the IMPT has created a dynamic network of experts with a shared commitment towards impactful MPT development

- The IMPT utilizes a product neutral lens to critically develop recommendations and guidance for MPT funders and product developers.
How can you support the MPT field and advance the lives of women and families worldwide?

- Include MPTs in your funding mandates to help address prioritized field wide gaps

- Assess how MPT products in the pipeline can align with your funding priorities

- Engage with other MPT funders through the MPT Supporting Agency Collaboration Committee (SACC)
Connect with the IMPT to learn more about MPT products in the pipeline and opportunities to advance solutions for women’s sexual and reproductive health.

www.theIMPT.org
This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government. The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, an organization dedicated to women’s reproductive health and empowerment, housed at the Public Health Institute (PHI).